Publications Archives

PRODUCTS
- Reagents
  ASRs
  Enzymes
  Hi-Di Formamide
- Product & Service Catalogs
CLINICAL LAB SERVICES
- Clinical Lab Services Overview
  The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.
  EXPLORE SERVICES ⟶
- Flow Cytometry
  Hematolymphoid Screening Panel
  AML MRD Assay
  CLL MRD Assay
- Companion Diagnostic (CDx) Tests
  CDx – USA
  CDx – Germany
  CDx – Japan
- NGS Cancer Panels
  MyAML
  MyMRD
- MRD NGS Tests
  Clonality
  FLT3 ITD
  NPM1
- Clonality NGS Tests
  SHM
  IGH
  IGK
  TRG
  TRB
BIOBANK REPOSITORY
DISEASES
- Lymphoid
  Mature B-cell
  Mature T-cell
  
  Lymphoma
  Lymphoma is a cancer that starts in cells that are part of the body’s immune system. Knowing which type of lymphoma you have is important because it affects your treatment options and your outlook (prognosis).
  
  LEARN MORE ⟶
- Myeloid
  Myelodysplastic Syndromes (MDS)
  Acute Myeloid Leukemia (AML)
  Myeloproliferative Neoplasms (MPNs)
  
  Myeloma
  Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.
  
  LEARN MORE ⟶
- Hematological Testing Menu
  Browse our comprehensive menu of product & testing services.
  EXPLORE MENU ⟶
PARTNERSHIPS
- Partnerships Overview
  A proven strategy to accelerate drug approvals
  EXPLORE PARTNERSHIPS ⟶
  CE-IVD
  LeukoStrat products are used worldwide to determine the mutation status of the FLT3 and NPM1 biomarkers.
  LEARN MORE ⟶
- Product Development
  Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays
  EXPLORE ⟶
  CE-IVD
  IdentiClone assays are intended for PCR-based detection of clonal gene rearrangements and translocations.
  LEARN MORE ⟶
- Manufacturing
  cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents
  EXPLORE ⟶
- LabPMM®
  Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment
  EXPLORE ⟶
- Global Regulatory Expertise
  Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)
  EXPLORE ⟶
SCIENCE
- Science Overview
  We take pride in expanding the science that bridges personalized medicine with quality healthcare.
  EXPLORE OUR SCIENCE ⟶
- Personalized Medicine
  Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.
  EXPLORE PERSONALIZED MEDICINE ⟶
PUBLICATIONS
- Featured Publication
  Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia
  VIEW PUBLICATION ⟶
- Latest Publications
  Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia
  VIEW PUBLICATION ⟶
  Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing
  VIEW PUBLICATION ⟶
  Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma
  VIEW PUBLICATION ⟶
COMPANY
- Company
  About Us
  Our Mission, Vision & Values
  Leadership Team
  Board of Directors
  Legal Notices
  Newsroom
  Global Distributors
  Licensure and Certifications
  Careers & Culture
  Shop Corporate Gear
- Invivoscribe Locations
  
  Invivoscribe, Inc. (USA)
  San Diego, CA, US
  CONTACT US ⟶
  
  Invivoscribe, SARL (France)
  Marseille, France
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  Shanghai, China
  CONTACT US ⟶
  Lymphoma
  Lymphoma is a cancer that starts in cells that are part of the body’s immune system. Knowing which type of lymphoma you have is important because it affects your treatment options and your outlook (prognosis).
  LEARN MORE ⟶
- Clinical Lab Locations
  
  LabPMM, LLC (USA)
  San Diego, CA, US
  CONTACT US ⟶
  
  LabPMM, GmbH (Germany)
  Munich, Germany
  CONTACT US ⟶
  
  LabPMM, GK (Japan)
  Kawasaki, Japan
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  Shanghai, China
  CONTACT US ⟶
  Myeloma
  Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.
  LEARN MORE ⟶
- Support
  
  Invivoscribe, Inc. (USA)
  CONTACT US ⟶
  
  Invivoscribe, SARL (France)
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  CONTACT US ⟶
  
  LabPMM, LLC (USA)
  CONTACT US ⟶
  
  LabPMM, GmbH (Germany)
  CONTACT US ⟶
  
  LabPMM, GK (Japan)
  CONTACT US ⟶
  Search for:
Search
- Search Articles & Publications
  Search for:
- Search Products & Services
  SEARCH ⟶
- Search Product Documents & IFUs
  SEARCH ⟶

← ALL PUBLICATIONS

Publications

From prognostication to precision in acute myeloid leukemia

Invivoscribe Marketing2025-05-08T16:47:49-07:00May 8th, 2025|2025 Publications, Featured Publications, Publications|

Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3 ITD mutated AML

Invivoscribe Marketing2025-05-09T09:20:30-07:00May 8th, 2025|2025 Publications, Featured Publications, Publications|

Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina^® MiSeq^TM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay

wmm2025-03-18T17:44:25-07:00November 8th, 2024|2024 Publications, Featured Publications, Publications|

Performance Comparison of Invivoscribe’s LymphoTrack^® Assays Between Complete Genomics DNBSEQ-G99 and Illumina^® MiSeq^TM NGS Platforms

wmm2025-03-18T17:44:43-07:00November 8th, 2024|2024 Publications, Featured Publications, Publications|

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

Invivoscribe Marketing2024-06-21T12:55:12-07:00June 21st, 2024|2024 Publications, Featured Publications, Publications|

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Invivoscribe Marketing2024-05-02T11:47:00-07:00May 2nd, 2024|2024 Publications, Featured Publications, Publications|

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Invivoscribe Marketing2024-03-26T13:55:01-07:00March 20th, 2024|2024 Publications, Featured Publications, Publications|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

Invivoscribe Marketing2024-03-26T13:50:51-07:00March 19th, 2024|2024 Publications, Featured Publications, Publications|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Invivoscribe Marketing2024-03-03T11:41:21-08:00March 1st, 2024|2024 Publications, Featured Publications, Publications|

Leveraging Standardized MRD Assays to Guide CLL Treatment

wmm2024-01-25T10:44:11-08:00January 25th, 2024|2024 Publications, Featured Publications, Publications|

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

wmm2023-04-10T20:22:16-07:00March 23rd, 2023|2023 Publications, Featured Publications, Publications|

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

Invivoscribe Marketing2024-08-02T14:22:45-07:00March 7th, 2023|2023 Publications, Featured Publications, Publications|

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

wmm2023-04-10T20:24:04-07:00March 2nd, 2023|2023 Publications, Featured Publications, Publications|

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

wmm2022-12-29T21:22:21-08:00November 15th, 2022|2022 Publications, Featured Publications, Publications|

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

wmm2022-12-29T21:19:31-08:00June 4th, 2022|2022 Publications, Featured Publications, Publications|

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

wmm2023-01-08T18:20:36-08:00May 30th, 2022|2022 Publications, Featured Publications, Publications|

Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma

Invivoscribe Marketing2022-09-07T22:22:23-07:00May 3rd, 2022|2022 Publications, Featured Publications, Publications|

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

wmm2022-01-06T05:38:03-08:00January 4th, 2022|2022 Publications, Featured Publications, Publications|

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL

wmm2022-01-08T23:37:03-08:00December 28th, 2021|2021 Publications, Publications|

Plan for a Successful International Drug Approval with Early Development of the Accompanying CDx

wmm2022-01-04T04:43:02-08:00December 8th, 2021|2021 Publications, Publications|

Machine Learning Algorithms Accelerate Throughput of a Flow – Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platform

wmm2022-01-30T21:35:17-08:00November 5th, 2021|2021 Publications, Publications|

Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing

Invivoscribe Marketing2022-09-07T22:31:04-07:00June 24th, 2021|2021 Publications, Featured Publications, Publications|

Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphoma

wmm2023-01-10T16:48:18-08:00April 28th, 2021|2022 Publications, Featured Publications, Publications|

Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

Invivoscribe Marketing2021-04-27T17:17:21-07:00April 20th, 2021|2021 Publications, Publications|

Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers

Invivoscribe Marketing2021-02-11T19:51:54-08:00November 25th, 2020|2020 Publications, Publications|

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

CE-IVD

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

CE-IVD

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.